China 'Definitely' Needs 2nd Covid Booster Dose: CanSino Biologics CEO

The transcript discusses China's transition in pandemic control policies and the rollout of inhaled vaccines. It covers the distribution of over 2 million doses, plans for future distribution, and the advantages of inhaled vaccines. The company has the capacity to produce billions of doses annually, with logistical ease favoring inhaled vaccines. Strategies to encourage elderly vaccination are highlighted, emphasizing convenience and safety. Financial performance is reviewed, with hopes for profitability in 2023, depending on vaccine uptake and new product rollouts.

What is the current status of China's transition time regarding pandemic control policies?

How many doses of the inhaled vaccine have been distributed so far?

What is the significance of mucosal immunity in the context of the inhaled vaccine?

How does the inhaled vaccine's administration differ from traditional injectable vaccines?

What are the advantages of the inhaled vaccine compared to the injectable vaccine?

What strategies can be employed to encourage the elderly population to take the vaccine?

What is the expected financial performance of the vaccine company in 2023?